FDA recalls 3 American Regent epinephrine lots, UAE clinics should verify emergency drug stock

American Regent recalled three U.S. lots of Epinephrine Injection, USP 30 mg/30 mL on 3 September 2026 after complaints of leaking and cracked multidose vials, according to a company notice posted by the U.S. Food and Drug Administration.

The highest-stakes readers are COOs, pharmacy heads and medical directors. Epinephrine is an emergency medicine used for anaphylaxis and septic-shock hypotension. Dubai clinics regulated by the Dubai Health Authority (DHA), Abu Dhabi and Al Ain facilities regulated by the Department of Health Abu Dhabi (DOH), and northern emirates providers regulated by the Ministry of Health and Prevention (MOHAP) should treat the notice as a stock-verification trigger, even if the FDA recall is U.S.-market specific.

What was recalled

The recalled product is American Regent Epinephrine Injection, USP 30 mg/30 mL (1 mg/mL), supplied as a multidose vial under NDC 0517-3030-01. The affected lots are 25128L1C0, 25280L1C0 and 26108L1C0. FDA said the lots were distributed in the United States between 4 September 2025 and 31 July 2026, with expiries in August 2026, October 2026 and July 2027.

"To date, American Regent has not received any reports of adverse events related to this recall." — American Regent company announcement posted by FDA

The company said complaints involved leaking and cracked vials, which created a lack of sterility assurance. Its investigation also identified particulate matter described as nylon, cellulosic, acrylic, polyethylene and glass. For medical directors, the risk is clinical rather than administrative. FDA said intravenous administration of particulate-contaminated epinephrine may cause vascular blockage, pulmonary embolism, organ damage or death.

UAE operational exposure

There is no public UAE recall notice identified in the FDA announcement. That limits the immediate legal interpretation. The operational question is narrower: did any UAE hospital, clinic, emergency cart supplier or pharmacy obtain the affected U.S. lots through a distributor, group-purchasing route or legacy stock movement?

COOs should ask pharmacy teams to complete a same-day lot check on crash carts, procedure rooms, dental sedation areas, allergy clinics and ambulance bags. The check should record product name, manufacturer, concentration, vial size, lot number, expiry date, storage location and supplier invoice. Any match should be quarantined pending instructions from the local supplier and the relevant UAE regulator.

• Dubai: route internal action through DHA-licensed pharmacy governance and supplier recall files.
• Abu Dhabi and Al Ain: DOH policy on quarantine and recall gives DOH pharmacovigilance a role in deciding Abu Dhabi market action after investigation.
• Northern emirates: MOHAP remains the relevant health regulator for healthcare facilities and medical product safety communications.
• Patient-facing pharmacies: verify whether the patient holds an auto-injector or a vial; this FDA recall concerns multidose vials, not EpiPen auto-injectors.

Finance teams should avoid using U.S. recall volume as a UAE cost proxy. The actionable number is local: count affected vials, replacement vials and missed emergency-cart minimums. UAE replacement pricing should be pulled from supplier invoices or the MOHAP registered medicine price file where available. For patient comparison, EpiPen Jr 0.15 mg auto-injector was listed by Life Pharmacy at AED 314.50 inclusive of VAT on 4 September 2026, but that is a different product format from the recalled American Regent vial.

What operators should do this week

Insurers including Daman, Thiqa and Sukoon may see limited direct claims exposure if the recalled product is held inside facility emergency stock rather than dispensed to members. The larger payer issue is continuity of anaphylaxis treatment. Pharmacy-benefit teams should confirm approved substitutes and any prior-authorisation rules for prescribed epinephrine auto-injectors, especially for paediatric allergy patients before the school term.

Medical directors should update staff briefings with one distinction: cracked multidose vials raise sterility and particulate risks, while auto-injector counselling still depends on expiry date, dose strength and patient technique. If a patient presents with a vial matching the recalled NDC or lot, clinicians should document the finding, advise replacement through a licensed pharmacy and report suspected harm through the relevant pharmacovigilance channel.

The practical close is a directory check. UAE operators and patients looking for licensed pharmacy providers should use the UAE Open Healthcare Directory, which lists more than 12,386 licensed healthcare providers across all seven emirates, then confirm stock availability and insurance acceptance directly with the pharmacy before travel.